Developing a multivariable prognostic model for pancreatic endocrine tumors using the clinical data warehouse resources of a single institution

OBJECTIVE: Current staging systems are not accurate for classifying pancreatic endocrine tumors (PETs) by risk. Here, we developed a prognostic model for PETs and compared it to the WHO classification system. METHODS: We identified 98 patients diagnosed with PET at NewYork-Presbyterian Hospital/Columbia University Medical Center (1999 to 2009). Tumor and clinical characteristics were retrieved and associations with survival were assessed by univariate Cox analysis. A multivariable model was constructed and a risk score was calculated; the prognostic strength of our model was assessed with the concordance index. RESULTS: Our cohort had median age of 60 years and consisted of 61.2% women; median follow-up time was 10.4 months (range: 0.1-99.6) with a 5-year survival of 61.5%. The majority of PETs were non-functional and no difference was observed between functional and non-functional tumors with respect to WHO stage, age, pathologic characteristics or survival. Distant metastases, aspartate aminotransferase-AST and surgical resection (HR=3.39, 95% CI: 1.38-8.35, p=0.008, HR=3.73, 95% CI: 1.20-11.57, p=0.023 and HR=0.20, 95% CI: 0.08-0.51, p<0.001 respectively) were the strongest predictors in the univariate analysis. Age, perineural and/or lymphovascular invasion, distant metastases and AST were the independent prognostic factors in the final multivariable model; a risk score was calculated and classified patients into low (n=40), intermediate (n=48) and high risk (n=10) groups. The concordance index of our model was 0.93 compared to 0.72 for the WHO system. CONCLUSION: Our prognostic model was highly accurate in stratifying patients by risk; novel approaches as such could thus be incorporated into clinical decisions.

[1]  F. Harrell,et al.  Evaluating the yield of medical tests. , 1982, JAMA.

[2]  A Rogier T Donders,et al.  Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example. , 2006, Journal of clinical epidemiology.

[3]  G. Petersen,et al.  Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  S. Choi,et al.  Malignant Nonfunctioning Endocrine Tumors of the Pancreas: Predictive Factors for Survival after Surgical Treatment , 2007, World Journal of Surgery.

[5]  J. Paulus,et al.  Alkaline Phosphatase Predicts Survival in Patients with Metastatic Neuroendocrine Tumors , 2006, Digestive Diseases and Sciences.

[6]  S. Asa,et al.  The Predictive Value of CK19 and CD99 in Pancreatic Endocrine Tumors , 2006, The American journal of surgical pathology.

[7]  H. Ohtani,et al.  World Health Organization Classification (2004)-based Re-evaluation of 95 nonfunctioning “malignant” pancreatic endocrine tumors reported in Japan , 2009, Surgery Today.

[8]  N. Probst-Hensch,et al.  WHO 2004 Criteria and CK19 are Reliable Prognostic Markers in Pancreatic Endocrine Tumors , 2007, The American journal of surgical pathology.

[9]  B. Skogseid,et al.  Prognostic Factors and Survival in 324 Patients with Pancreatic Endocrine Tumor Treated at a Single Institution , 2008, Clinical Cancer Research.

[10]  Laura H. Tang,et al.  Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Ko,et al.  Prognostic Score Predicting Survival After Resection of Pancreatic Neuroendocrine Tumors: Analysis of 3851 Patients , 2008, Annals of surgery.

[12]  M. Farnell,et al.  Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. , 2008, Endocrine-related cancer.

[13]  H. Pitt,et al.  Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients , 1998, Journal of Gastrointestinal Surgery.

[14]  H. Reber,et al.  Resection of pancreatic neuroendocrine tumors: results of 70 cases. , 2006, Archives of surgery.

[15]  B. Stenkvist,et al.  Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material , 2004, Virchows Archiv A.

[16]  R. Kronmal,et al.  Multiple imputation of baseline data in the cardiovascular health study. , 2003, American journal of epidemiology.

[17]  C. Doglioni,et al.  Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. , 2009, Human pathology.

[18]  H. Friess,et al.  Clinical outcome and long‐term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas , 2008, The British journal of surgery.

[19]  I. Modlin,et al.  An analysis of 8305 cases of carcinoid tumors , 2000, Cancer.

[20]  Peter C Austin,et al.  Bootstrap Methods for Developing Predictive Models , 2004 .

[21]  Judy L. Smith,et al.  Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas , 2002, Annals of Surgical Oncology.

[22]  Douglas G Altman,et al.  Developing a prognostic model in the presence of missing data: an ovarian cancer case study. , 2003, Journal of clinical epidemiology.

[23]  D G Altman,et al.  A prognostic model for ovarian cancer , 2001, British Journal of Cancer.

[24]  D. Santini,et al.  Endocrine pancreatic tumors: factors correlated with survival. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  D. Ballard,et al.  Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. , 1991, Mayo Clinic proceedings.

[26]  G. Klöppel,et al.  The Gastroenteropancreatic Neuroendocrine Cell System and Its Tumors: The WHO Classification , 2004, Annals of the New York Academy of Sciences.

[27]  Y. Morioka,et al.  Clinical pathology of endocrine tumors of the pancreas , 1991, Digestive Diseases and Sciences.

[28]  V. Deshpande,et al.  Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. , 2007, Archives of surgery.

[29]  H. Boshuizen,et al.  Multiple imputation of missing blood pressure covariates in survival analysis. , 1999, Statistics in medicine.

[30]  B. Weinhold Epigenetics: The Science of Change , 2006, Virchows Archiv.

[31]  D. Klimstra,et al.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.